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Chiral amides via copper-catalysed
enantioselective conjugate addition
Anne K. Schoonen,a M. Ángeles Fernández-Ibáñez,a,b Martín Fañanás-Mastral,a
Johannes F. Teicherta,c and Ben L. Feringa*a
A highly enantioselective one pot procedure for the synthesis of
β-substituted amides was developed starting from the corres-
ponding α,β-unsaturated esters. This new methodology is based
on the copper-catalysed enantioselective conjugate addition of
Grignard reagents to α,β-unsaturated esters and subsequent direct
formation of amides by quenching the corresponding enolates
with diﬀerent amines. Various primary and secondary amines
bearing alkyl or aryl substituents can be used giving rise to a large
variety of β-substituted amides with excellent enantioselectivities.
Introduction
The catalytic asymmetric conjugate addition (CA) of organo-
metallic reagents to α,β-unsaturated compounds is one of the
most versatile methodologies for the formation of C–C bonds.1
In 2004, a highly enantioselective catalytic CA of Grignard
reagents was reported from our laboratories.2 This paved the
way for the eﬃcient enantioselective CA of Grignard reagents
to α,β-unsaturated ketones,3 esters4,5 and thioesters6 using
catalysts based on Josiphos type ligands (L1 or L2)4 and
various copper salts (Fig. 1). The group of Loh reported an
alternative for the enantioselective CA to α,β-unsaturated esters
with a catalyst consisting of Tol-BINAP (L3)5 and copper iodide
(Fig. 1). Despite this progress, as far as we know only one
method has been described for the enantioselective CA of
Grignard reagents to α,β-unsaturated amides, with enantio-
selectivities ranging from 30 to 74%.7 This paucity in examples
is probably due to the low intrinsic reactivity of α,β-unsatu-
rated amides compared to esters and ketones.8 This limited
the formation of chiral amides, one of the most common
structural motifs in modern pharmaceuticals and biologically
active compounds.9
Chiral β-substituted amides can be obtained with high
stereoselectivities via the CA of Grignard reagents to α,β-
unsaturated amides bearing (S,S)-pseudoephedrine as a chiral
auxiliary.7,10,11 The addition proceeds both with7 and
without10,11 copper as a catalyst. However, to obtain the
desired chiral β-alkyl substituted amides via this route two
additional steps are required: one to remove the auxiliary by
hydrolysis and another to obtain the corresponding amide.
An alternative method to obtain β-alkyl substituted amides
comprises the asymmetric CA of boron compounds to α,β-
unsaturated amides (including 5,6-dihydro-2(1H)-pyridinones).
This has been achieved via rhodium-catalysed addition of aryl-
boron12 reagents and via copper-catalysed addition of
diboron13 reagents. However, these methods do not allow the
introduction of alkyl groups to furnish β-alkyl substituted
amides. Therefore the formation of β-alkyl substituted chiral
amides remains a challenging target as this structure is
present in many biologically active compounds including
cyclotheonamide E414 and orbiculamide A.15
In this context, the copper-catalysed enantioselective CA of
dialkylzinc reagents to α,β-unsaturated N-acyloxazolidinones16
has been reported to provide the corresponding chiral β-alkyl
compounds. The desired chiral β-alkyl substituted amide can
be obtained from the corresponding oxazolidinones in one
additional step. Furthermore, the copper-catalysed enantio-
selective CA to α,β-unsaturated lactams has been described
with alkylzinc reagents17 and alkyl- and alkenylalananes17,18
giving rise to β-substituted lactams in good yields and
Fig. 1 Diphosphine ligands used in Cu-catalysed asymmetric CA.
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selectivities. There is also one example of the asymmetric CA
of Me3Al to an N-acylpyrrole derivative in which the corres-
ponding methylated product is obtained in 54% yield and
96% ee.19
Recently, we discovered that β-alkyl substituted amides
could be obtained directly by quenching a cyclic ester enolate
with propylamine.20 This enolate was formed during the
enantioselective CA of EtMgBr to coumarins; quenching with
propylamine gave the corresponding amide in a good yield
without compromising the ee of the enantioselective CA
product. Inspired by this result, we envisioned a one pot pro-
cedure for the synthesis of β-alkyl substituted amides consist-
ing of first the enantioselective CA of Grignard reagents to an
acyclic α,β-unsaturated ester and subsequent in situ quenching
with an amine to obtain the corresponding amide (Scheme 1).
Herein, we present a new one pot method to obtain β-alkyl
substituted amides in an asymmetric fashion, in which the
amide formation occurs without the need for additional
reagents or reaction steps.
Results and discussion
For this one pot procedure, we focused on the optimisation of
the amide formation after the enantioselective CA step, which
was carried out with ligand L1 and CuBr·SMe2 at −75 °C as
previously reported.4 We optimised the reaction conditions
and determined that the use of 3.0 equiv. of amine and
stirring the reaction mixture at room temperature overnight
(ca. 14 h) were the optimised conditions.
For our investigations, we used α,β-unsaturated esters 1 and
2 as model substrates, because of their high enantioselec-
tivities in the CA of Grignard reagents and as they represent
substrates bearing alkyl or aryl substituents.21,22
The enantioselective CA to substrates 1 and 2 was per-
formed, with EtMgBr (1.5 equiv.), CuBr·SMe2 (5 mol%) and L1
(7.5 mol%) in methyl tert-butyl ether (MTBE).4 Subsequently
the intermediate enolate was quenched in situ with various
amines and allowed to react under the optimised reaction con-
ditions for amide formation (Table 1).
Scheme 1 Catalytic asymmetric CA to esters and in situ formation of
amides.
Table 1 Scope for the one pot two step procedure
Entry Ester Amine Product Yielda (%) eeb (%)
1 65 92
2 73 88
3 77 (75)c 93 (92)c
4 64 87
5 54 93
6 79 91
7 50 93
8 40 98
a Isolated yields. bDetermined by chiral GC (entry 1) or chiral HPLC analysis. c Carried out on a 7.8 mmol (1.0 g) scale.
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We found that the reaction of α,β-unsaturated esters 1 and
2 with 3.0 equiv. of aniline provided the corresponding amides
4 and 5 with good yields (65% and 73%, respectively) and
excellent enantioselectivities, revealing that no racemisation
occurs during the process (entries 1 and 2). The reaction using
p-bromoaniline furnished amide 6 with good yield (77%)
without compromising the ee (entry 3). We also carried out the
reaction employing benzylamine and similar results were
obtained (entry 4).
In order to broaden the amine scope, the reaction was
carried out with the secondary N-methylbenzylamine giving
rise to the corresponding amides 8 and 9 with synthetically
useful yields (entries 5 and 6). Finally, the reaction was per-
formed with aliphatic propylamine, which yields amide 10 in
moderate yield and excellent ee (entry 7).23 In addition, this
method has been employed to obtain the biologically active
amide 1124 with 40% yield and 98% ee in a one pot two step
synthesis starting from commercially available materials
(entry 8).
To underscore the synthetic utility of this method, we
performed the one pot synthesis of amide 6 on a large scale
(entry 3) starting from 1.0 g (7.8 mmol) of the α,β-unsaturated
ester 1 and we obtained 1.8 g (75% yield) of amide 6 with
92% ee.
Finally, we employed diﬀerent Grignard reagents including
the less reactive MeMgBr (Fig. 2). The reaction using
n-HexMgBr and benzylamine furnished the amide 12 with
good yield (63%) and excellent ee. In addition, the Me group is
introduced employing the conditions of Loh et al.5b followed
by the addition of aniline, which aﬀorded the amide 13 in
moderate yield (47%) but excellent enantioselectivity.
Conclusions
In conclusion, we have developed a highly enantioselective one
pot procedure for the synthesis of β-substituted amides start-
ing from the corresponding α,β-unsaturated esters. This new
methodology is based on the previously developed copper-cata-
lysed asymmetric CA of Grignard reagents to α,β-unsaturated
esters and the subsequent direct formation of the corres-
ponding amides by quenching the enolate with an amine
without the need of extra reagents. This methodology is
compatible with a range of α,β-unsaturated esters, Grignard
reagents and amines, including primary and secondary
amines bearing alkyl or aryl substituents. Importantly, this
one pot two-step process occurs without racemisation. Further-
more, the robustness of the process is demonstrated by
performing the reaction on a 1.0 g scale. Further synthetic
applications are in progress.
Experimental
General methods
Chromatography: Merck silica gel type 9385 230–400 mesh,
TLC: Merck silica gel 60, 0.25 mm. Components were visual-
ized by UV and cerium/molybdenum staining. Mass spectra
were recorded on a LTQ Orbitrap XL (ESI+). 1H- and 13C-NMR
were recorded on a Varian AMX400 (400 and 100 MHz, respecti-
vely) or a Varian Mercury Plus (200 and 50 MHz, respectively)
using CDCl3 as a solvent. Chemical shift values are reported in
ppm with the solvent resonance as the internal standard
(CHCl3: δ 7.26 for
1H, δ 77.16 for 13C). Optical rotations were
measured using a Schmidt+Haensch polarimeter (Polartronic
MH8) with a 10 cm cell (c given in g per 100 mL). Enantio-
meric excesses were determined by HPLC analysis using a
Shimadzu LC-10ADVP HPLC equipped with a Shimadzu
SPD-M10AVP diode array detector or by capillary GC analysis
(Chiraldex B-PM (30 m × 0.25 mm × 0.25 µm)) using a flame
ionization detector. All reactions were carried out under a
nitrogen atmosphere using flame-dried glassware and using
standard Schlenk techniques. Dichloromethane and MTBE
were dried using the solvent purification system SPS 800 from
MBraun. Substrates 2 and 3 were synthesised according to
literature procedures.20,21 Methyl trans-cinnamate (4), copper
salts (CuI and copper(I) bromide dimethylsulfide
complex (CuBr)), propylamine and N-benzylmethylamine, all
Grignard reagents (MeMgBr (3.0 M in Et2O), EtMgBr (3.0 M in
Et2O), n-HexMgBr (2.0 M in Et2O)), ligands L2 and L3 were
purchased from Aldrich. The benzylamine was purchased
from Acros and aniline from Merck; all amines were distilled
before use.
General procedure for the amide synthesis
In a Schlenk tube equipped with a septum and a stirring bar,
L2 (6.7 mg, 10.5 µmol) and CuBr·SMe2 (1.85 mg, 9.0 µmol)
were dissolved in MTBE (1.0 mL) and the mixture was stirred
under nitrogen at r.t. for 20 min. The mixture was then cooled
to −75 °C and the Grignard reagent (0.45 mmol in solution)
was added. After stirring for 5 min, a solution of the substrate
(0.3 mmol) in MTBE (0.20 mL) was added dropwise over 1 h.
After stirring at −75 °C for two additional hours, the corres-
ponding amine (0.9 mmol) was added and the reaction
mixture was stirred overnight while being slowly warmed to r.t.
Subsequently a saturated aqueous solution of NH4Cl (2 mL)
was added. After extraction with CH2Cl2 (3 × 10 mL) the com-
bined organic phases were dried over MgSO4 and concentrated
under reduced pressure. The crude product was purified using
flash chromatography on silica gel (pentane–EtOAc as an
eluent) to yield the pure product.25
(R)-3-Ethyl-N-phenylhexanamide (4). Amide 4 was obtained
from (E)-methyl 2-hexenoate (64 mg, 0.5 mmol) following
the general procedure, after purification by column
Fig. 2 Diﬀerent alkyl Grignard reagents.
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chromatography on silica (pentane–EtOAc; 9/1), as a pale
yellow oil (65%, 71 mg) with 92% ee. [α]20D = +47 (c 1.0 in
CHCl3);
1H NMR (300 MHz) δ 7.52 (d, J = 7.9 Hz, 2H),
7.44–7.18 (m, 2H), 7.08 (t, J = 7.4 Hz, 1H), 2.26 (d, J = 7.0 Hz,
2H), 2.00–1.82 (m, 1H), 1.50–1.28 (m, 6H), 0.89 (t, J = 7.3 Hz,
6H); 13C NMR (50 MHz) δ 171.3 (CvO), 138.0 (C), 128.93 (CH),
124.1 (CH), 119.8 (CH), 42.5 (CH2), 36.6 (CH), 35.6 (CH2), 26.2
(CH2), 19.8 (CH2), 14.4 (CH3), 10.8 (CH3); HRMS (APCI
+, m/z):
calculated for C14H22NO [M + H
+]: 220.1696, found: 220.1696;
enantiomeric excess was determined by chiral HPLC analysis,
Chiralcel OD-H column, n-heptane–i-PrOH 95 : 5, 40 °C,
0.5 mL min−1, 213 nm, retention times (min) t1: 34.74 (minor)
and t2: 38.93 (major).
(R)-3-Ethyl-N-phenyl-5-phenylpentanamide (5). Amide 5 was
obtained starting from (E)-methyl 5-phenyl-2-pentenoate
(95 mg, 0.5 mmol) following the general procedure, after puri-
fication by column chromatography on silica (pentane–EtOAc;
9/1), as a pale yellow oil (73%, 102 mg) oil with 88% ee. [α]20D =
−7 (c 1.0 in CHCl3); 1H NMR (200 MHz) δ 7.50 (m, 3H), 7.21
(m, 7H), 2.78–2.51 (m, 2H), 2.32 (d, J = 7.0 Hz, 2H), 2.17–1.83
(m, 1H), 1.83–1.57 (m, 2H), 1.57–1.34 (m, 2H), 0.93 (t, J =
7.4 Hz, 3H); 13C NMR (50 MHz) δ 171.1 (CvO), 142.5 (C), 138.0
(C), 128.9 (CH), 128.4 (CH), 128.3 (CH), 125.8 (CH), 124.2 (CH),
120.0 (CH), 42.3 (CH2), 36.6 (CH), 35.2 (CH2), 33.0 (CH2), 26.1
(CH2), 10.7. (CH3); HRMS (APCI
+, m/z): calculated for
C16H26NO [M + H
+]: 281.1852, found: 282.1853; enantiomeric
excess was determined by chiral HPLC analysis, Chiralcel
OD-H column, n-heptane–i-PrOH 90 : 10, 40 °C, 0.5 mL min−1,
213 nm, retention times (min) t1: 12.8 (minor) and t2: 14.10
(major).
(R)-N-(4-Bromophenyl)-3-ethylhexanamide (6). Amide 6 was
obtained starting from (E)-methyl 2-hexenoate (37 mg,
0.3 mmol) following the general procedure, after purification
by column chromatography on silica (pentane–Et2O; 9/1), as a
white solid (77%, 69 mg) with 93% ee. [α]20D = −9 (c 1.0 in
CHCl3);
1H NMR (300 MHz) δ 7.42 (s, 4H), 7.12 (s, NH), 2.25
(d, J = 7.0 Hz, 2H), 1.99–1.79 (m, 1H), 1.49–1.12 (m, 6H),
0.94–0.80 (m, 6H); 13C NMR (75 MHz) δ 171.4 (CvO), 136.9
(C), 132.1 (CH), 121.6 (CH), 118.7 (CBr), 42.8 (CH2), 36.8 (CH),
35.9 (CH2), 26.5 (CH2), 20.0 (CH2), 14.5 (CH3), 11.0 (CH3);
HRMS (APCI+, m/z): calculated for C14H21BrNO [M + H
+]:
298.0801, found: 298.0803; enantiomeric excess was deter-
mined by chiral HPLC analysis, Chiralcel OJ-H column,
n-heptane–i-PrOH 98 : 2, 40 °C, 0.5 mL min−1, 249 nm, reten-
tion times (min) t1: 47.7 (major) and t2: 49.6 (minor).
(R)-N-Benzyl-3-ethyl-5-phenylpentanamide (7). Amide 7 was
obtained starting from (E)-methyl 5-phenyl-2-pentenoate
(58 mg, 0.3 mmol) following the general procedure, after puri-
fication by column chromatography on silica (pentane–EtOAc;
9/1), as a pale yellow oil (64%, 42 mg) with 87% ee. [α]20D = +8
(c 1.0 in CHCl3);
1H NMR (400 MHz) δ 7.24 (m, 10H), 5.67 (br
s, NH), 4.46 (dd, J = 12.7, 3.8 Hz, 1H) 4.42 (dd, J = 12.9, 3.6 Hz,
1H), 2.62 (td, J = 13.8, 8.2, Hz, 1H), 2.60 (td, J = 13.4, 8.3 Hz,
1H), 2.21 (dd, J = 14.3, 7.2 Hz, 1H), 2.14 (dd, J = 14.3, 7.2 Hz,
1H) 1.89 (sept, J = 6.5 Hz, 1H), 1.69–1.59 (m, 2H), 1.48–1.33
(m, 2H), 0.91 (t, J = 7.4 Hz, 3H); 13C NMR (50 MHz) δ 172.3
(CvO), 142.6 (C), 138.4 (C), 128.7 (CH), 128.3 (CH), 128.3
(CH), 127.9 (CH), 127.5 (CH), 125.7 (CH), 43.6 (CH2N), 41.3
(CH2), 36.5 (CH), 35.2 (CH2), 33.0 (CH2), 26.1 (CH2), 10.7
(CH3); HRMS (APCI
+, m/z): calculated for C20H26NO [M + H
+]:
296.2009, found: 296.2008; enantiomeric excess was deter-
mined by chiral HPLC analysis, Chiralcel OD-H column,
n-heptane–i-PrOH 90 : 10, 40 °C, 0.5 mL min−1, 212 nm, reten-
tion times (min) t1: 25.12 (minor) and t2: 28.53 (major).
(R)-N-Benzyl-3-ethyl-N-methylhexanamide (8). Amide 8 was
obtained starting from (E)-methyl 2-hexenoate (64 mg,
0.5 mmol) following the general procedure, after purification
by column chromatography on silica (pentane–EtOAc; 9/1), as
a pale yellow oil (54%, 67 mg) with 93% ee (2 : 3 mixture of
conformers A and B). [α]20D = +39 (c 1.0 in CHCl3);
1H NMR
(400 MHz) δ 7.45–7.20 (m, 4H), 7.16 (d, J = 7.4 Hz, 1H), 4.60 (s,
NCH2Ph, conformer A), 4.54 (s, NCH2Ph, conformer B) 2.94 (s,
NCH3, conformer B), 2.92 (s, NCH3, conformer A), 2.34–2.25
(m, 2H), 2.05–1.78 (m, 1H), 1.45–1.20 (m, 6H), 1.01–0.77 (m,
6H); 13C NMR (50 MHz) δ 173.4 (CvO), 173.0 (CvO), 137.7
(C), 128.9 (CH), 128.5 (CH), 128.0 (CH), 127.5 (CH), 127.2 (CH),
126.3 (CH), 53.4 (CH2), 50.8 (CH2), 37.8 (CH2), 37.5 (CH2), 36.1
(CH3), 36.0 (CH3), 35.8 (CH), 35.7 (CH), 26.3 (CH2), 26.2 (CH2),
19.8 (CH2), 14.4 (CH3), 10.9 (CH3); HRMS (APCI
+, m/z): calcu-
lated for C16H26NO [M + H
+]: 248.2009, found: 248.2015;
enantiomeric excess was determined by chiral HPLC analysis,
Chiralcel OJ-H column, n-heptane–i-PrOH 98 : 02, 40 °C,
0.5 mL min−1, 212 nm, retention times (min) t1: 13.12 (minor)
and t2: 13.87 (major).
(R)-N-Benzyl-3-ethyl-N-methyl-5-phenylpentanamide (9).
Amide 9 was obtained starting from (E)-methyl 5-phenyl-2-pente-
noate (95 mg, 0.5 mmol) following the general procedure,
after purification by column chromatography on silica
(pentane–EtOAc; 9/1), as a pale yellow oil (79%, 122 mg) with
91% ee (4 : 5 mixture of conformers A and B). [α]20D = −10 (c 1.0
in CHCl3);
1H NMR (200 MHz) δ 7.31 (m, 10H), 4.60 (s,
NCH2Ph, conformer B), 4.52 (s, NCH2Ph, conformer A) 2.94 (s,
NCH3, conformer A), 2.89 (s, NCH3, conformer B), 2.61 (m,
2H), 2.35 (m, 2H), 2.16–1.92 (m, 1H), 1.77–1.54 (m, 2H),
1.54–1.35 (m, 2H), 0.94 (t, J = 5.9 Hz, 3H, conformer B), 0.87 (t,
J = 5.8 Hz, 3H, conformer A); 13C NMR (50 MHz) δ 173.3.0
(CvO), 172.7 (CvO), 142.7 (C), 137.6 (C), 136.8 (C), 129.6
(CH), 128.9 (CH), 128.8 (CH), 128.5 (CH), 128.4 (CH), 128.3
(CH), 128.0 (CH), 127.5 (CH), 127.3 (CH), 126.3 (CH), 125.6
(CH), 53.9 (CH2), 50.9 (CH2), 37.7 (CH2), 37.4 (CH2) 36.0 (CH),
35.4 (CH3), 35.3 (CH2), 33.1 (CH2), 26.3 (CH2), 26.2 (CH2), 10.8
(CH3); HRMS (APCI
+, m/z): calculated for C21H28NO [M + H
+]:
310.2165, found: 310.2167; enantiomeric excess was deter-
mined by chiral HPLC analysis, Chiralcel OJ-H column,
n-heptane–i-PrOH 95 : 5, 40 °C, 0.5 mL min−1, 212 nm, reten-
tion times (min) t1: 24.97 (minor) and t2: 26.45 (major).
(R)-3-Ethyl-N-propylhexanamide (10). Amide 10 was
obtained starting from (E)-methyl 2-hexenoate (38 mg,
0.3 mmol) following the general procedure, after purification
by column chromatography on silica (pentane–EtOAc; 9/1), as
a pale yellow oil (52%, 25 mg) with 96% ee. [α]20D = +3 (c 1.0 in
CHCl3);
1H NMR (400 MHz) δ 5.49 (s, 1H), 3.22 (t, J = 6.8 Hz,
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1H), 3.19 (t, J = 6.6 Hz, 1H), 2.10–1.98 (m, 2H), 1.82 (m, 1H),
1.57–1.41 (m, 2H), 1.40–1.13 (m, 6H), 0.91 (t, J = 7.4 Hz, 3H),
0.88 (t, J = 6.9 Hz, 3H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR
(50 MHz) δ 172.8 (CvO), 41.6 (CH2), 41.1 (CH2), 36.5 (CH),
35.6 (CH2), 26.0 (CH2), 22.9 (CH2), 19.7 (CH2), 14.3 (CH3), 11.3
(CH3), 10.7 (CH3); HRMS (APCI
+, m/z): calculated for C11H24NO
[M + H+]: 186.1852, found: 186.1850; enantiomeric excess was
determined by chiral GC analysis, Chiraldex B-PM column,
T 110 (5 min), 120 (5 min), 130 (5 min), 135 (15 min), ΔT 5 °C
min−1, retention times (min) t1: 27.54 (major) and t2: 28.83
(minor).
(S)-3-Methyl-N-phenethylpentanamide (11). Amide 11 was
obtained starting from methyl crotonate (50 mg, 0.5 mmol) fol-
lowing the general procedure, after purification by column
chromatography on silica (pentane–Et2O; 1/1), as a pale yellow
oil (40%, 44 mg) with 98% ee. [α]20D = +3 (c 1.0 in CHCl3);
1H
NMR (400 MHz) δ 7.31 (t, J = 7.3 Hz, 2H), 7.24 (d, J = 7.1 Hz,
1H), 7.19 (d, J = 7.3 Hz, 2H), 5.42 (br s, NH), 3.54 (t, J = 6.5 Hz,
1H), 3.53 (t, J = 6.4 Hz, 1H), 2.82 (t, J = 6.8 Hz, 2H), 2.13 (m,
1H), 2.02–1.78 (m, 2H), 1.42–1.09 (m, 2H), 0.88 (d, J = 4.7 Hz,
3H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (50 MHz) δ 172.6 (CvO),
138.9 (C), 128.7 (CH), 128.6 (CH), 126.4 (CH), 44.2 (CH2), 40.4
(CH2), 35.8 (CH2), 32.3 (CH), 29.3 (CH2), 19.1 (CH3), 11.3
(CH3); HRMS (APCI
+, m/z): calculated for C14H22NO [M + H
+]:
220.1697, found: 220.1696; enantiomeric excess was deter-
mined by chiral HPLC analysis, Chiralcel OD-H column,
n-heptane–i-PrOH 98 : 2, 40 °C, 0.5 mL min−1, 212 nm,
retention times (min) t1: 28.60 (major) and t2: 35.59 (minor).
(R)-N-Benzyl-3-phenethylnonanamide (12). Amide 12 was
obtained starting from (E)-methyl 5-phenyl-2-pentenoate
(58 mg, 0.3 mmol) following the general procedure, after puri-
fication by column chromatography on silica (pentane–EtOAc;
9/1), as a pale yellow oil (63%, 67 mg) with 90% ee. [α]20D = −1
(c 1.0 in CHCl3);
1H NMR (400 MHz) δ 7.44–7.20 (m, 7H),
7.20–7.03 (m, 3H), 5.64 (br t, J = 4.8 Hz, 1H), 4.43 (d, J = 5.7 Hz,
2H), 2.62 (t, J = 6.4 Hz, 1H), 2.61 (t, J = 6.3 Hz, 1H) 2.25–2.12
(m, 2H), 1.97 (m, 1H), 1.72–1.45 (m, 2H), 1.45–1.15 (m, 10H),
0.88 (t, J = 6.5 Hz, 3H); 13C NMR (50 MHz) δ 172.4 (CvO),
142.6 (C), 138.4 (C), 128.7 (CH), 128.3 (CH), 128.3 (CH), 127.9
(CH), 127.5 (CH), 125.7 (CH), 43.6 (CH2), 41.8 (CH2), 35.7 (CH),
35.3 (CH2), 33.7 (CH2), 33.0 (CH2), 31.9 (CH2), 29.0 (CH2), 26.4
(CH2), 22.7 (CH2), 14.1 (CH3); HRMS (APCI
+, m/z): calculated
for C24H34NO [M + H
+]: 352.2635, found: 352.2632; enantio-
meric excess was determined by chiral HPLC analysis,
Chiralcel OD-H column, n-heptane–i-PrOH 90 : 10, 40 °C,
0.5 mL min−1, 212 nm, retention times (min) t1: 21.26 (minor)
and t2: 22.52 (major).
(R)-3-Methyl-N-phenylhexanamide (13). In a Schlenk tube
equipped with a septum and a stirring bar, (S)-Tol-Binap
(10.2 mg, 15 µmol) and CuI (1.91 mg, 10 µmol) were dissolved
in MTBE (1 mL) and the mixture stirred under nitrogen atmos-
phere at r.t. for 20 min. The mixture was then cooled to −20 °C
and MeMgBr (2.5 mmol) was added. After stirring for 5 min, a
solution of (E)-methyl 2-hexenoate (37 mg, 0.3 mmol) in MTBE
(0.2 mL) was added dropwise over 1 h. After stirring for two
additional hours, the temperature was lowered to −75 °C, the
amine (3.0 mmol) was added and the reaction mixture was
stirred overnight while being slowly warmed to r.t. Sub-
sequently a saturated aqueous solution of NH4Cl (2 mL) was
added. After extraction with DCM (3 × 10 mL) the combined
organic phases were dried and concentrated to an oil which
was purified using column chromatography on silica
(pentane–EtOAc; 9/1), yielding the pure product as a pale
yellow oil (47%, 29.2 mg) with 95% ee. [α]20D = +1 (c 1.0 in
CHCl3);
1H NMR (400 MHz) δ 7.51 (d, J = 7.9 Hz, 2H), 7.31 (t,
J = 7.9 Hz, 2H), 7.08 (t, J = 7.4 Hz, 1H), 2.44–2.24 (m, 1H),
2.19–1.97 (m, 2H), 1.45–1.13 (m, 4H), 0.98 (d, J = 6.3 Hz, 3H),
0.90 (t, J = 6.9 Hz, 3H); 13C NMR (50 MHz) δ 171.0 (CvO),
137.9 (C), 128.9 (CH), 124.1 (CH), 119.8 (CH), 45.6 (CH2), 39.1
(CH), 30.6 (CH2), 20.1 (CH2), 19.6 (CH3), 14.2 (CH3); HRMS
(APCI+, m/z): calculated for C13H20NO [M + H
+]: 206.1539,
found: 206.1540; enantiomeric excess was determined by
chiral HPLC analysis, Chiralcel OD-H column, n-heptane–
i-PrOH 95 : 5, 40 °C, 0.5 mL min−1, 254 nm, retention times
(min) t1: 35.38 (minor) and t2: 43.70 (major).
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